Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC—First B.E.A.TrialScott Berry, Eric VanCutsem, Beatrix Lutiger et al.|Journal of Clinical Oncology|2006Cited by 44
Receipt and survival outcomes by age following second-line therapy for metastatic CRC (mCRC): Analysis of 5,289 patients from the ARCAD Clinical Trials Program.Nadine J. McCleary, Stuart M. Lichtman, William S. Harmsen et al.|Journal of Clinical Oncology|2020Cited by 1
Survival outcomes among older adults (OA) receiving second-line therapy for metastatic CRC (mCRC): 5,289 patients (pts) from the ARCAD Clinical Trials Program.Nadine J. McCleary, Qian Shi, William S. Harmsen et al.|Journal of Clinical Oncology|2020Cited by 0